Back to search

Ciba-Geigy Limited: Pharmaceutical Division (A)

By Reinhard Angelmar,  Yves L. Doz,  Francesca Gee
Published 01 Jan 1988
Reference 4242
Topic Strategy
Industry Pharmaceuticals
Region Global
Length 18 page(s)
Language English
Inspection copy
6.00
Add to cart
Summary

Abstract: See Advanced Drug Delivery Systems: ALZA and Ciba-Geigy (A) - (F).

Keywords
  • HEALTHCARE
  • AR1988
  • AR1992
Related cases to use with this case

Ciba-Geigy Limited: Pharmaceutical Division (B)

By  Reinhard Angelmar,  Yves L. Doz,  Francesca Gee

    Add to cart

    Ciba-Geigy Limited: Pharmaceutical Division (C)

    By  Reinhard Angelmar,  Yves L. Doz,  Francesca Gee

      Add to cart

      Ciba-Geigy Limited: Pharmaceutical Division (Synopsis)

      By  Yves L. Doz

        Add to cart
        About the authors
        Angelmar

        Reinhard Angelmar

        Emeritus Professor of Marketing
        Doz

        Yves L. Doz

        Emeritus Professor of Strategic Management

        Francesca Gee


        Recommended Cases

        Ciba-Geigy France: Agricultural Division

        By  Reinhard Angelmar
        Add to cart Free Case
        The marketing manager of Ciba-Geigy's Agro Division in France must recommend a marketing strategy and marketing mix for a new fungicide. The degree of market coverage and whether to take an undifferentiated or a differentiated approach are the major issues.
          View case

          Ranbaxy Laboratories Limited: At the Crossroads

          By  Amitava Chattopadhyay,  Swati Srivastava
          Add to cart
          The case describes challenges facing Ranbaxy, the third largest pharmaceutical company in India, as it attempts to move from being a generics marketer, to a player in the branded drugs business. The case focuses on issues relating to the launch of Cifran OD, Ranbaxy's first drug based on a patented new drug delivery system.
            View case

            Eli Lilly Multi-Drug Resistant Tuberculosis Partnership

            By  Hans Wahl,  Bruce Kogut
            Add to cart
            Once thought eradicated, turbuculosis has infected millions in the last decades throughout Russia, Asia, and Africa, because of its evolving virulence due to inadequate medical delivery. With its TB drugs out of patent, Eli Lilly decided nevertheless to invest $70 million into partnerships to assure that the drug delivery is properly administered.
              View case